GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer’s disease

Frontiers in Cellular Neuroscience

Volumn 8, Issue , 2014, Pages

  Nava Mesa, Mauricio O ^a   Jiménez Díaz, Lydia ^b   Yajeya, Javier ^c   Navarro Lopez, Juan D ^b  

^a UNIVERSIDAD DEL ROSARIO   (Colombia)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Alzheimer s disease; Amyloid peptide; Excitatory and inhibitory neurotransmission; Learning and memory; Septohippocampal system

Indexed keywords

ADENOSINE A2A RECEPTOR; AMPA RECEPTOR; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BENZODIAZEPINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM CHANNEL L TYPE; DIZOCILPINE; LEVETIRACETAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERVE GROWTH FACTOR; POTASSIUM CHANNEL KCNQ2;

ADRENERGIC TRANSMISSION; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTIFICIAL NEURAL NETWORK; BRAIN ATROPHY; COGNITION; DOWN SYNDROME; GABAERGIC TRANSMISSION; HIPPOCAMPUS; HUMAN; LEARNING; MEMORY DISORDER; META ANALYSIS (TOPIC); MYOCLONUS; NERVE DEGENERATION; NERVE EXCITABILITY; NEUROMODULATION; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SYNAPTIC MEMBRANE; SYSTEMATIC REVIEW (TOPIC);

EID: 85017836789     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2014.00167     Document Type: Review

References (309)

1. Aisen, P. S., Gauthier, S., Ferris, S. H., Saumier, D., Haine, D., Garceau, D., et al. (2011). Tramiprosate in mild-to-moderate Alzheimer’s disease-a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch. Med. Sci. 7, 102-111. doi: 10.5114/aoms.2011.20612
2. Aisen, P. S., Saumier, D., Briand, R., Laurin, J., Gervais, F., Tremblay, P., et al. (2006). A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 67, 1757-1763. doi: 10.1212/01.wnl.0000244346.08950.64
3. Allegri, R. F., and Guekht, A. (2012). Cerebrolysin improves symptoms and delays progression in patients with Alzheimer’s disease and vascular dementia. Drugs Today (Barc.) 48(Suppl. A), 25-41. doi: 10.1358/dot.2012.48(Suppl.A).1739721
4. Alvarez, X. A., Cacabelos, R., Sampedro, C., Couceiro, V., Aleixandre, M., Vargas, M., et al. (2011). Combination treatment in Alzheimer’s disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Curr. Alzheimer Res. 8, 583-591. doi: 10.2174/156720511796391863
5. Amaral, D. G., and Bassett, J. L. (1989). Cholinergic innervation of the monkey amygdala: an immunohistochemical analysis with antisera to choline acetyltransferase. J. Comp. Neurol. 281, 337-361. doi: 10.1002/cne.902810303
6. Amunts, K., Kedo, O., Kindler, M., Pieperhoff, P., Mohlberg, H., Shah, N. J., et al. (2005). Cytoarchitectonic mapping of the human amygdala, hippocampal region and entorhinal cortex: intersubject variability and probability maps. Anat. Embryol. (Berl.) 210, 343-352. doi: 10.1007/s00429-005-0025-5
7. Araque, A., Parpura, V., Sanzgiri, R. P., and Haydon, P. G. (1998). Glutamate-dependent astrocyte modulation of synaptic transmission between cultured hippocampal neurons. Eur. J. Neurosci. 10, 2129-2142. doi: 10.1046/j.1460-9568.1998.00221.x
8. Araque, A., Parpura, V., Sanzgiri, R. P., and Haydon, P. G. (1999). Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci. 22, 208-215. doi: 10.1016/S0166-2236(98)01349-6
9. Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., and Hyman, B. T. (1992). Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42, 631-639. doi: 10.1212/WNL.42.3.631
10. Ashenafi, S., Fuente, A., Criado, J. M., Riolobos, A. S., Heredia, M., and Yajeya, J. (2005). Beta-amyloid peptide25-35 depresses excitatory synaptic transmission in the rat basolateral amygdala "in vitro." Neurobiol. Aging 26, 419-428. doi: 10.1016/j.neurobiolaging.2004.05.008
11. Atack, J. R. (2010). Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA. Pharmacol. Ther. 125, 11-26. doi: 10.1016/j.pharmthera.2009.09.001
12. Baglietto-Vargas, D., Moreno-Gonzalez, I., Sanchez-Varo, R., Jimenez, S., Trujillo-Estrada, L., Sanchez-Mejias, E., et al. (2010). Calretinin interneurons are early targets of extracellular amyloid-beta pathology in PS1/AbetaPP Alzheimer mice hippocampus. J. Alzheimers Dis. 21, 119-132. doi: 10.3233/JAD-2010-100066
13. Bak, L. K., Schousboe, A., and Waagepetersen, H. S. (2006). The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J. Neurochem. 98, 641-653. doi: 10.1111/j.1471-4159.2006.03913.x
14. Bastiaansen, M., and Hagoort, P. (2003). Event-induced theta responses as a window on the dynamics of memory. Cortex 39, 967-992. doi: 10.1016/S0010-9452(08)70873-6
15. Baum, L., Chen, L., Ng, H. K., and Pang, C. P. (2000). Apolipoprotein E isoforms in Alzheimer’s disease pathology and etiology. Microsc. Res. Tech. 50, 278-281. doi: 10.1002/1097-0029(20000815)50:4<278::AID-JEMT5>3.0.CO;2-T
16. Bernareggi, A., Duenas, Z., Reyes-Ruiz, J. M., Ruzzier, F., and Miledi, R. (2007). Properties of glutamate receptors of Alzheimer’s disease brain transplanted to frog oocytes. Proc. Natl. Acad. Sci. U.S.A. 104, 2956-2960. doi: 10.1073/pnas.0611513104
17. Bienvenu, T. C., Busti, D., Magill, P. J., Ferraguti, F., and Capogna, M. (2012). Cell-type-specific recruitment of amygdala interneurons to hippocampal theta rhythm and noxious stimuli in vivo. Neuron 74, 1059-1074. doi: 10.1016/j.neuron.2012.04.022
18. Bissonette, G. B., Bae, M. H., Suresh, T., Jaffe, D. E., and Powell, E. M. (2014). Prefrontal cognitive deficits in mice with altered cerebral cortical GABAergic interneurons. Behav. Brain Res. 259, 143-151. doi: 10.1016/j.bbr.2013.10.051
19. Bland, B. H., and Colom, L. V. (1993). Extrinsic and intrinsic properties underlying oscillation and synchrony in limbic cortex. Prog. Neurobiol. 41, 157-208. doi: 10.1016/0301-0082(93)90007-F
20. Bland, B. H., and Oddie, S. D. (2001). Theta band oscillation and synchrony in the hippocampal formation and associated structures: the case for its role in sensorimotor integration. Behav. Brain Res. 127, 119-136. doi: 10.1016/S0166-4328(01)00358-8
21. Bland, B. H., Derie-Gillespie, D., Mestek, P., Jackson, J., Crooks, R., and Cormican, A. (2007). To move or not: previous experience in a runway avoidance task determines the appearance of hippocampal Type 2 sensory processing theta. Behav. Brain Res. 179, 299-304. doi: 10.1016/j.bbr.2007.02.002
22. Bolton, M. M., Heaney, C. F., Sabbagh, J. J., Murtishaw, A. S., Magcalas, C. M., and Kinney, J. W. (2012). Deficits in emotional learning and memory in an animal model of schizophrenia. Behav. Brain Res. 233, 35-44. doi: 10.1016/j.bbr.2012.04.049
23. Borhegyi, Z., Varga, V., Szilagyi, N., Fabo, D., and Freund, T. F. (2004). Phase segregation of medial septal GABAergic neurons during hippocampal theta activity. J. Neurosci. 24, 8470-8479. doi: 10.1523/JNEUROSCI.1413-04.2004
24. Bowery, N. G. (2006). GABAB receptor: a site of therapeutic benefit. Curr. Opin. Pharmacol. 6, 37-43. doi: 10.1016/j.coph.2005.10.002
25. Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., et al. (2002). Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-511. doi: 10.1038/416507a
26. Busche, M. A., Eichhoff, G., Adelsberger, H., Abramowski, D., Wiederhold, K. H., Haass, C., et al. (2008). Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer’s disease. Science 321, 1686-1689. doi: 10.1126/science.1162844
27. Buzsaki, G. (2002). Theta oscillations in the hippocampus. Neuron 33, 325-340. doi: 10.1016/S0896-6273(02)00586-X
28. Caccamo, A., Fisher, A., and LaFerla, F. M. (2009). M1 agonists as a potential disease-modifying therapy for Alzheimer’s disease. Curr. Alzheimer Res. 6, 112-117. doi: 10.2174/156720509787602915
29. Caccamo, A., Oddo, S., Billings, L. M., Green, K. N., Martinez-Coria, H., Fisher, A., et al. (2006). M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49, 671-682. doi: 10.1016/j.neuron.2006.01.020
30. Calza, L., Baldassarro, V. A., Giuliani, A., Lorenzini, L., Fernandez, M., Mangano, C., et al. (2013). From the multifactorial nature of Alzheimer’s disease to multitarget therapy: the contribution of the translational approach. Curr. Top. Med. Chem. 13, 1843-1852. doi: 10.2174/15680266113139990140
31. Canas, P. M., Simoes, A. P., Rodrigues, R. J., and Cunha, R. A. (2014). Predominant loss of glutamatergic terminal markers in a beta-amyloid peptide model of Alzheimer’s disease. Neuropharmacology 76(Pt A), 51-56. doi: 10.1016/j.neuropharm.2013.08.026
32. Cardinali, D. P., and Golombek, D. A. (1998). The rhythmic GABAergic system. Neurochem. Res. 23, 607-614. doi: 10.1023/A:1022426519297
33. Carlsen, J. (1988). Immunocytochemical localization of glutamate decarboxylase in the rat basolateral amygdaloid nucleus, with special reference to GABAergic innervation of amygdalostriatal projection neurons. J. Comp. Neurol. 273, 513-526. doi: 10.1002/cne.902730407
34. Carlsen, J., and Heimer, L. (1988). The basolateral amygdaloid complex as a cortical-like structure. Brain Res. 441, 377-380. doi: 10.1016/0006-8993(88)91418-7
35. Casas, C., Sergeant, N., Itier, J. M., Blanchard, V., Wirths, O., van der Kolk, N., et al. (2004). Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am. J. Pathol. 165, 1289-1300. doi: 10.1016/S0002-9440(10)63388-3
36. Castañeda, M. T., Sanabria, E. R., Hernandez, S., Ayala, A., Reyna, T. A., Wu, J. Y., et al. (2005). Glutamic acid decarboxylase isoforms are differentially distributed in the septal region of the rat. Neurosci. Res. 52, 107-119. doi: 10.1016/j.neures.2005.02.003
37. Chapouthier, G. (1989). The search for a biochemistry of memory. Arch. Gerontol. Geriatr. Suppl. 1, 7-19.
38. Chen, L., Yamada, K., Nabeshima, T., and Sokabe, M. (2006). alpha7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats. Neuropharmacology 50, 254-268. doi: 10.1016/j.neuropharm.2005.09.018
39. Chen, Q. S., Kagan, B. L., Hirakura, Y., and Xie, C. W. (2000). Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J. Neurosci. Res. 60, 65-72. doi: 10.1002/(SICI)1097-4547(20000401)60:1<65::AID-JNR7>3.0.CO;2-Q
40. Chu, D. C., Penney, J. B. Jr., and Young, A. B. (1987). Quantitative autoradiography of hippocampal GABAB and GABAA receptor changes in Alzheimer’s disease. Neurosci. Lett. 82, 246-252. doi: 10.1016/0304-3940(87)90264-3
41. Ciruela, F., Fernandez-Duenas, V., Sahlholm, K., Fernandez-Alacid, L., Nicolau, J. C., Watanabe, M., et al. (2010). Evidence for oligomerization between GABAB receptors and GIRK channels containing the GIRK1 and GIRK3 subunits. Eur. J. Neurosci. 32, 1265-1277. doi: 10.1111/j.1460-9568.2010.07356.x
42. Cohen-Gadol, A. A., Pan, J. W., Kim, J. H., Spencer, D. D., and Hetherington, H. H. (2004). Mesial temporal lobe epilepsy: a proton magnetic resonance spectroscopy study and a histopathological analysis. J. Neurosurg. 101, 613-620. doi: 10.3171/jns.2004.101.4.0613
43. Colom, L. V. (2006). Septal networks: relevance to theta rhythm, epilepsy and Alzheimer’s disease. J. Neurochem. 96, 609-623. doi: 10.1111/j.1471-4159.2005.03630.x
44. Colom, L. V., Castaneda, M. T., Banuelos, C., Puras, G., Garcia-Hernandez, A., Hernandez, S., et al. (2010). Medial septal beta-amyloid 1-40 injections alter septo-hippocampal anatomy and function. Neurobiol. Aging 31, 46-57. doi: 10.1016/j.neurobiolaging.2008.05.006
45. Colom, L. V., and Garrido-Sanabria, E. (2007). Modulation of normal and altered hippocampal excitability states by septal networks. J. Neurosci. Res. 85, 2839-2843. doi: 10.1002/jnr.21276
46. Cooper, A., Grigoryan, G., Guy-David, L., Tsoory, M. M., Chen, A., and Reuveny, E. (2012). Trisomy of the G protein-coupled K+ channel gene, Kcnj6, affects reward mechanisms, cognitive functions, and synaptic plasticity in mice. Proc. Natl. Acad. Sci. U.S.A. 109, 2642-2647. doi: 10.1073/pnas.1109099109
47. Coyle, J. T., Price, D. L., and DeLong, M. R. (1983). Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 219, 1184-1190. doi: 10.1126/science.6338589
48. Cudaback, E., Jorstad, N. L., Yang, Y., Montine, T. J., and Keene, C. D. (2014). Therapeutic implications of the prostaglandin pathway in Alzheimer’s disease. Biochem. Pharmacol. 88, 565-572. doi: 10.1016/j.bcp.2013.12.014
49. Cullen, W. K., Suh, Y. H., Anwyl, R., and Rowan, M. J. (1997). Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport 8, 3213-3217. doi: 10.1097/00001756-199710200-00006
50. Cummings, J. L., and Cole, G. (2002). Alzheimer disease. J. Am. Med. Assoc. 287, 2335-2338. doi: 10.1001/jama.287.18.2335
51. Cutsuridis, V., Cobb, S., and Graham, B. P. (2010). Encoding and retrieval in a model of the hippocampal CA1 microcircuit. Hippocampus 20, 423-446. doi: 10.1002/hipo.20661
52. Cutsuridis, V., and Hasselmo, M. (2012). GABAergic contributions to gating, timing, and phase precession of hippocampal neuronal activity during theta oscillations. Hippocampus 22, 1597-1621. doi: 10.1002/hipo.21002
53. Dabir, D. V., Trojanowski, J. Q., Richter-Landsberg, C., Lee, V. M., and Forman, M. S. (2004). Expression of the small heat-shock protein alphaB-crystallin in tauopathies with glial pathology. Am. J. Pathol. 164, 155-166. doi: 10.1016/S0002-9440(10)63106-9
54. Danysz, W., Parsons, C. G., Mobius, H. J., Stoffler, A., and Quack, G. (2000). Neuroprotective and symptomatological action of memantine relevant for Alzheimer’s disease-a unified glutamatergic hypothesis on the mechanism of action. Neurotox. Res. 2, 85-97. doi: 10.1007/BF03033787
55. Days, E., Kaufmann, K., Romaine, I., Niswender, C., Lewis, M., Utley, T., et al. (2010). Discovery and Characterization of a Selective Activator of the G-Protein Activated Inward-Rectifying Potassium (GIRK) Channel. Probe Reports from the NIH Molecular Libraries Program. Bethesda, MD: National Center for Biotechnology Information. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23762945
56. De Simone, R., Puig, X. S., Gelisse, P., Crespel, A., and Genton, P. (2010). Senile myoclonic epilepsy: delineation of a common condition associated with Alzheimer’s disease in Down syndrome. Seizure 19, 383-389. doi: 10.1016/j.seizure.2010.04.008
57. de Vivo, L., Melone, M., Rothstein, J. D., and Conti, F. (2010). GLT-1 promoter activity in astrocytes and neurons of mouse hippocampus and somatic sensory cortex. Front. Neuroanat. 3:31. doi: 10.3389/neuro.05.031.2009
58. Devi, L., and Ohno, M. (2010). Genetic reductions of beta-site amyloid precursor protein-cleaving enzyme 1 and amyloid-beta ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer’s disease model mice. Eur. J. Neurosci. 31, 110-118. doi: 10.1111/j.1460-9568.2009.07031.x
59. Diekelmann, S., and Born, J. (2010). The memory function of sleep. Nat. Rev. Neurosci. 11, 114-126. doi: 10.1038/nrn2762
60. Ding, S., Fellin, T., Zhu, Y., Lee, S. Y., Auberson, Y. P., Meaney, D. F., et al. (2007). Enhanced astrocytic Ca2+ signals contribute to neuronal excitotoxicity after status epilepticus. J. Neurosci. 27, 10674-10684. doi: 10.1523/JNEUROSCI.2001-07.2007
61. Double, K. L., Reyes, S., Werry, E. L., and Halliday, G. M. (2010). Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Prog. Neurobiol. 92, 316-329. doi: 10.1016/j.pneurobio.2010.06.001
62. Dougherty, J. J., Wu, J., and Nichols, R. A. (2003). Beta-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J. Neurosci. 23, 6740-6747.
63. Duran-Gonzalez, J., Michi, E. D., Elorza, B., Perez-Cordova, M. G., Pacheco-Otalora, L. F., Touhami, A., et al. (2013). Amyloid beta peptides modify the expression of antioxidant repair enzymes and a potassium channel in the septohippocampal system. Neurobiol. Aging 34, 2071-2076. doi: 10.1016/j.neurobiolaging.2013.02.005
64. Dziewczapolski, G., Glogowski, C. M., Masliah, E., and Heinemann, S. F. (2009). Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer’s disease. J. Neurosci. 29, 8805-8815. doi: 10.1523/JNEUROSCI.6159-08.2009
65. Emre, M., Geula, C., Ransil, B. J., and Mesulam, M. M. (1992). The acute neurotoxicity and effects upon cholinergic axons of intracerebrally injected beta-amyloid in the rat brain. Neurobiol. Aging 13, 553-559. doi: 10.1016/0197-4580(92)90055-3
66. Emson, P. C. (2007). GABA(B) receptors: structure and function. Prog. Brain Res. 160, 43-57. doi: 10.1016/S0079-6123(06)60004-6
67. España, J., Gimenez-Llort, L., Valero, J., Minano, A., Rabano, A., Rodriguez-Alvarez, J., et al. (2010). Intraneuronal beta-amyloid accumulation in the amygdale enhances fear and anxiety in Alzheimer’s disease transgenic mice. Biol. Psychiatry 67, 513-521. doi: 10.1016/j.biopsych.2009.06.015
68. Farlow, M. R. (2009). Treatment of mild cognitive impairment (MCI). Curr. Alzheimer Res. 6, 362-367. doi: 10.2174/156720509788929282
69. Farr, S. A., Uezu, K., Creonte, T. A., Flood, J. F., and Morley, J. E. (2000). Modulation of memory processing in the cingulate cortex of mice. Pharmacol. Biochem. Behav. 65, 363-368. doi: 10.1016/S0091-3057(99)00226-9
70. Fell, J., Klaver, P., Lehnertz, K., Grunwald, T., Schaller, C., Elger, C. E., et al. (2001). Human memory formation is accompanied by rhinal-hippocampal coupling and decoupling. Nat. Neurosci. 4, 1259-1264. doi: 10.1038/nn759
71. Fellin, T., Pascual, O., Gobbo, S., Pozzan, T., Haydon, P. G., and Carmignoto, G. (2004). Neuronal synchrony mediated by astrocytic glutamate through activation of extrasynaptic NMDA receptors. Neuron 43, 729-743. doi: 10.1016/j.neuron.2004.08.011
72. Fernandez, F., Morishita, W., Zuniga, E., Nguyen, J., Blank, M., Malenka, R. C., et al. (2007). Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 10, 411-413. doi: 10.1038/nn1860
73. Fields, R. D., Araque, A., Johansen-Berg, H., Lim, S. S., Lynch, G., Nave, K. A., et al. (2014). Glial biology in learning and cognition. Neuroscientist doi: 10.1177/1073858413504465 [Epub ahead of print].
74. Fisher, A., Brandeis, R., Bar-Ner, R. H., Kliger-Spatz, M., Natan, N., Sonego, H., et al. (2002). AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer’s disease. J. Mol. Neurosci. 19, 145-153. doi: 10.1007/s12031-002-0025-3
75. Forman, M. S., Lal, D., Zhang, B., Dabir, D. V., Swanson, E., Lee, V. M., et al. (2005). Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration. J. Neurosci. 25, 3539-3550. doi: 10.1523/JNEUROSCI.0081-05.2005
76. Freir, D. B., Holscher, C., and Herron, C. E. (2001). Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. J. Neurophysiol. 85, 708-713.
77. Freund, T. F., and Antal, M. (1988). GABA-containing neurons in the septum control inhibitory interneurons in the hippocampus. Nature 336, 170-173. doi: 10.1038/336170a0
78. Fries, P., Reynolds, J. H., Rorie, A. E., and Desimone, R. (2001). Modulation of oscillatory neuronal synchronization by selective visual attention. Science 291, 1560-1563. doi: 10.1126/science.1055465
79. Froestl, W. (2010). Chemistry and pharmacology of GABAB receptor ligands. Adv. Pharmacol. 58, 19-62. doi: 10.1016/S1054-3589(10)58002-5
80. Fu, W., Ruangkittisakul, A., MacTavish, D., Shi, J. Y., Ballanyi, K., and Jhamandas, J. H. (2012). Amyloid beta (Abeta) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways. J. Biol. Chem. 287, 18820-18830. doi: 10.1074/jbc.M111.331181
81. Fujii, S., Ji, Z., and Sumikawa, K. (2000). Inactivation of alpha7 ACh receptors and activation of non-alpha7 ACh receptors both contribute to long term potentiation induction in the hippocampal CA1 region. Neurosci. Lett. 286, 134-138. doi: 10.1016/S0304-3940(00)01076-4
82. Gallacher, J., Elwood, P., Pickering, J., Bayer, A., Fish, M., and Ben-Shlomo, Y. (2012). Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J. Epidemiol. Community Health 66, 869-873. doi: 10.1136/jech-2011-200314
83. Genkova-Papazova, M. G., Petkova, B., Shishkova, N., and Lazarova-Bakarova, M. (2000). The GABA-B antagonist CGP 36742 prevent PTZ-kindling-provoked amnesia in rats. Eur. Neuropsychopharmacol. 10, 273-278. doi: 10.1016/S0924-977X(00)00082-1
84. Gervais, F., Paquette, J., Morissette, C., Krzywkowski, P., Yu, M., Azzi, M., et al. (2007). Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging 28, 537-547. doi: 10.1016/j.neurobiolaging.2006.02.015
85. Giannakopoulos, P., Kovari, E., Gold, G., von, G. A., Hof, P. R., and Bouras, C. (2009). Pathological substrates of cognitive decline in Alzheimer’s disease. Front. Neurol. Neurosci. 24:20-29. doi: 10.1159/000197881
86. Gill, K. M., and Grace, A. A. (2013). Differential effects of acute and repeated stress on hippocampus and amygdala inputs to the nucleus accumbens shell. Int. J. Neuropsychopharmacol. 16, 2013-2025. doi: 10.1017/S1461145713000618
87. Girod, R., Barazangi, N., McGehee, D., and Role, L. W. (2000). Facilitation of glutamatergic neurotransmission by presynaptic nicotinic acetylcholine receptors. Neuropharmacology 39, 2715-2725. doi: 10.1016/S0028-3908(00)00145-3
88. Goedert, M., and Spillantini, M. G. (2006). A century of Alzheimer’s disease. Science 314, 777-781. doi: 10.1126/science.1132814
89. Gong, N., Li, Y., Cai, G. Q., Niu, R. F., Fang, Q., Wu, K., et al. (2009). GABA transporter-1 activity modulates hippocampal theta oscillation and theta burst stimulation-induced long-term potentiation. J. Neurosci. 29, 15836-15845. doi: 10.1523/JNEUROSCI.4643-09.2009
90. Gonzalez, R. G., Fischman, A. J., Guimaraes, A. R., Carr, C. A., Stern, C. E., Halpern, E. F., et al. (1995). Functional MR in the evaluation of dementia: correlation of abnormal dynamic cerebral blood volume measurements with changes in cerebral metabolism on positron emission tomography with fludeoxyglucose F 18. Am. J. Neuroradiol. 16, 1763-1770.
91. Gordon, G. R., Baimoukhametova, D. V., Hewitt, S. A., Rajapaksha, W. R., Fisher, T. E., and Bains, J. S. (2005). Norepinephrine triggers release of glial ATP to increase postsynaptic efficacy. Nat. Neurosci. 8, 1078-1086. doi: 10.1038/nn1498
92. Goutagny, R., and Krantic, S. (2013). Hippocampal oscillatory activity in Alzheimer’s disease: toward the identification of early biomarkers? Aging Dis. 4, 134-140.
93. Gu, Z., Zhong, P., and Yan, Z. (2003). Activation of muscarinic receptors inhibits beta-amyloid peptide-induced signaling in cortical slices. J. Biol. Chem. 278, 17546-17556. doi: 10.1074/jbc.M209892200
94. Gutala, R., Wang, J., Hwang, Y. Y., Haq, R., and Li, M. D. (2006). Nicotine modulates expression of amyloid precursor protein and amyloid precursor-like protein 2 in mouse brain and in SH-SY5Y neuroblastoma cells. Brain Res. 1093, 12-19. doi: 10.1016/j.brainres.2006.03.100
95. Halassa, M. M., Fellin, T., and Haydon, P. G. (2007). The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol. Med. 13, 54-63. doi: 10.1016/j.molmed.2006.12.005
96. Hangya, B., Borhegyi, Z., Szilagyi, N., Freund, T. F., and Varga, V. (2009). GABAergic neurons of the medial septum lead the hippocampal network during theta activity. J. Neurosci. 29, 8094-8102. doi: 10.1523/JNEUROSCI.5665-08.2009
97. Harkany, T., De Jong, G. I., Soos, K., Penke, B., Luiten, P. G., and Gulya, K. (1995). Beta-amyloid (1-42) affects cholinergic but not parvalbumin-containing neurons in the septal complex of the rat. Brain Res. 698, 270-274. doi: 10.1016/0006-8993(95)01013-L
98. Harkany, T., Mulder, J., Sasvari, M., Abraham, I., Konya, C., Zarandi, M., et al. (1999). N-methyl-D-aspartate receptor antagonist MK-801 and radical scavengers protect cholinergic nucleus basalis neurons against beta-amyloid neurotoxicity. Neurobiol. Dis. 6, 109-121. doi: 10.1006/nbdi.1998.0230
99. Harris, G. J., Lewis, R. F., Satlin, A., English, C. D., Scott, T. M., Yurgelun-Todd, D. A., et al. (1998). Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: a promising alternative to nuclear medicine. Am. J. Neuroradiol. 19, 1727-1732.
100. Hasselmo, M. E. (2005). What is the function of hippocampal theta rhythm?-linking behavioral data to phasic properties of field potential and unit recording data. Hippocampus 15, 936-949. doi: 10.1002/hipo.20116
101. Heese, K., Otten, U., Mathivet, P., Raiteri, M., Marescaux, C., and Bernasconi, R. (2000). GABA(B) receptor antagonists elevate both mRNA and protein levels of the neurotrophins nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) but not neurotrophin-3 (NT-3) in brain and spinal cord of rats. Neuropharmacology 39, 449-462. doi: 10.1016/S0028-3908(99)00166-5
102. Heimer, L., de Olmos, J. S., Alheid, G. F., Pearson, J., Sakamoto, N., Shinoda, K., et al. (1999). "The human basal forebrain Part II," in Handbook of Chemical Neuroanatomy: The Primate Nervous System, eds T. Hokfelt, A. Bjorklund, and F. Bloom (Amsterdam: Elsevier Science), 57-226.
103. Heinrichs, S. C., Leite-Morris, K. A., Carey, R. J., and Kaplan, G. B. (2010). Baclofen enhances extinction of opiate conditioned place preference. Behav. Brain Res. 207, 353-359. doi: 10.1016/j.bbr.2009.10.013
104. Henderson, Z., and Jones, G. A. (2005). GABAB receptors in the medial septum/diagonal band slice from 16-25 day rat. Neuroscience 132, 789-800. doi: 10.1016/j.neuroscience.2005.01.027
105. Hertz, L. (2013). The glutamate-glutamine (GABA) cycle: importance of late postnatal development and potential reciprocal interactions between biosynthesis and degradation. Front. Endocrinol. (Lausanne) 4:59. doi: 10.3389/fendo.2013.00059
106. Hickman, S. E., Allison, E. K., and El, K. J. (2008). Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer’s disease mice. J. Neurosci. 28, 8354-8360. doi: 10.1523/JNEUROSCI.0616-08.2008
107. Hof, P. R., and Morrison, J. H. (1991). Neocortical neuronal subpopulations labeled by a monoclonal antibody to calbindin exhibit differential vulnerability in Alzheimer’s disease. Exp. Neurol. 111, 293-301. doi: 10.1016/0014-4886(91)90096-U
108. Hopper, M. W., and Vogel, F. S. (1976). The limbic system in Alzheimer’s disease. A neuropathologic investigation. Am. J. Pathol. 85, 1-20.
109. Howell, O., Atack, J. R., Dewar, D., McKernan, R. M., and Sur, C. (2000). Density and pharmacology of alpha5 subunit-containing GABA(A) receptors are preserved in hippocampus of Alzheimer’s disease patients. Neuroscience 98, 669-675. doi: 10.1016/S0306-4522(00)00163-9
110. Hsieh, H., Boehm, J., Sato, C., Iwatsubo, T., Tomita, T., Sisodia, S., et al. (2006). AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52, 831-843. doi: 10.1016/j.neuron.2006.10.035
111. Huang, J., Chen, Y. J., Bian, W. H., Yu, J., Zhao, Y. W., and Liu, X. Y. (2010). Unilateral amyloid-beta25-35 injection into the rat amygdala increases the expressions of aberrant tau phosphorylation kinases. Chin. Med. J. (Engl.) 123, 1311-1314.
112. Huang, Y., and Mucke, L. (2012). Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222. doi: 10.1016/j.cell.2012.02.040
113. Huh, C. Y., Goutagny, R., and Williams, S. (2010). Glutamatergic neurons of the mouse medial septum and diagonal band of Broca synaptically drive hippocampal pyramidal cells: relevance for hippocampal theta rhythm. J. Neurosci. 30, 15951-15961. doi: 10.1523/JNEUROSCI.3663-10.2010
114. Iwakiri, M., Mizukami, K., Ikonomovic, M. D., Ishikawa, M., Abrahamson, E. E., DeKosky, S. T., et al. (2009). An immunohistochemical study of GABA A receptor gamma subunits in Alzheimer’s disease hippocampus: relationship to neurofibrillary tangle progression. Neuropathology 29, 263-269. doi: 10.1111/j.1440-1789.2008.00978.x
115. Iwakiri, M., Mizukami, K., Ikonomovic, M. D., Ishikawa, M., Hidaka, S., Abrahamson, E. E., et al. (2005). Changes in hippocampal GABABR1 subunit expression in Alzheimer’s patients: association with Braak staging. Acta Neuropathol. 109, 467-474. doi: 10.1007/s00401-005-0985-9
116. Janickova, H., Rudajev, V., Zimcik, P., Jakubik, J., Tanila, H., El-Fakahany, E. E., et al. (2013). Uncoupling of M1 muscarinic receptor/G-protein interaction by amyloid beta(1-42). Neuropharmacology 67, 272-283. doi: 10.1016/j.neuropharm.2012.11.014
117. Jimenez-Jimenez, F. J., Molina, J. A., Gomez, P., Vargas, C., de, B. F., Benito-Leon, J., et al. (1998). Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer’s disease. J. Neural. Transm. 105, 269-277. doi: 10.1007/s007020050073
118. John, J. P., Sunyer, B., Hoger, H., Pollak, A., and Lubec, G. (2009). Hippocampal synapsin isoform levels are linked to spatial memory enhancement by SGS742. Hippocampus 19, 731-738. doi: 10.1002/hipo.20553
119. Jourdain, P., Bergersen, L. H., Bhaukaurally, K., Bezzi, P., Santello, M., Domercq, M., et al. (2007). Glutamate exocytosis from astrocytes controls synaptic strength. Nat. Neurosci. 10, 331-339. doi: 10.1038/nn1849
120. Kaifosh, P., Lovett-Barron, M., Turi, G. F., Reardon, T. R., and Losonczy, A. (2013). Septo-hippocampal GABAergic signaling across multiple modalities in awake mice. Nat. Neurosci. 16, 1182-1184. doi: 10.1038/nn.3482
121. Kar, S., Seto, D., Gaudreau, P., and Quirion, R. (1996). Beta-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal slices. J. Neurosci. 16, 1034-1040.
122. Kaufmann, K., Romaine, I., Days, E., Pascual, C., Malik, A., Yang, L., et al. (2013). ML297 (VU0456810), the first potent and selective activator of the GIRK potassium channel, displays antiepileptic properties in mice. ACS Chem. Neurosci. 4, 1278-1286. doi: 10.1021/cn400062a
123. Kaupmann, K., Schuler, V., Mosbacher, J., Bischoff, S., Bittiger, H., Heid, J., et al. (1998). Human gamma-aminobutyric acid type B receptors are differentially expressed and regulate inwardly rectifying K+ channels. Proc. Natl. Acad. Sci. U.S.A. 95, 14991-14996. doi: 10.1073/pnas.95.25.14991
124. Kelly, B. L., Vassar, R., and Ferreira, A. (2005). Beta-amyloid-induced dynamin 1 depletion in hippocampal neurons. A potential mechanism for early cognitive decline in Alzheimer disease. J. Biol. Chem. 280, 31746-31753. doi: 10.1074/jbc.M503259200
125. Kem, W. R. (2000). The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer’s disease: studies with DMXBA (GTS-21). Behav. Brain Res. 113, 169-181. doi: 10.1016/S0166-4328(00)00211-4
126. Kimura, H., McGeer, P. L., Peng, F., and McGeer, E. G. (1980). Choline acetyltransferase-containing neurons in rodent brain demonstrated by immunohisto chemistry. Science 208, 1057-1059. doi: 10.1126/science.6990490
127. Klein, W. L. (2002). ADDLs & protofibrils-the missing links? Neurobiol. Aging 23, 231-235. doi: 10.1016/S0197-4580(01)00312-8
128. Klingner, M., Apelt, J., Kumar, A., Sorger, D., Sabri, O., Steinbach, J., et al. (2003). Alterations in cholinergic and non-cholinergic neurotransmitter receptor densities in transgenic Tg2576 mouse brain with beta-amyloid plaque pathology. Int. J. Dev. Neurosci. 21, 357-369. doi: 10.1016/j.ijdevneu.2003.08.001
129. Kobayashi, T., Ikeda, K., Kojima, H., Niki, H., Yano, R., Yoshioka, T., et al. (1999). Ethanol opens G-protein-activated inwardly rectifying K+ channels. Nat. Neurosci. 2, 1091-1097. doi: 10.1038/16019
130. Kohl, M. M., and Paulsen, O. (2010). The roles of GABAB receptors in cortical network activity. Adv. Pharmacol. 58, 205-229. doi: 10.1016/S1054-3589(10)58009-8
131. Kohler, C., Chan-Palay, V., and Wu, J. Y. (1984). Septal neurons containing glutamic acid decarboxylase immunoreactivity project to the hippocampal region in the rat brain. Anat. Embryol. (Berl) 169, 41-44. doi: 10.1007/BF00300585
132. Kommers, T., Rodnight, R., Boeck, C., Vendite, D., Oliveira, D., Horn, J., et al. (2002). Phosphorylation of glial fibrillary acidic protein is stimulated by glutamate via NMDA receptors in cortical microslices and in mixed neuronal/glial cell cultures prepared from the cerebellum. Brain Res. Dev. Brain Res. 137, 139-148. doi: 10.1016/S0165-3806(02)00434-0
133. Komori, T. (1999). Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick’s disease. Brain Pathol. 9, 663-679. doi: 10.1111/j.1750-3639.1999.tb00549.x
134. Kulik, A., Vida, I., Lujan, R., Haas, C. A., Lopez-Bendito, G., Shigemoto, R., et al. (2003). Subcellular localization of metabotropic GABA(B) receptor subunits GABA(B1a/b) and GABA(B2) in the rat hippocampus. J. Neurosci. 23, 11026-11035.
135. Lafon-Cazal, M., Viennois, G., Kuhn, R., Malitschek, B., Pin, J. P., Shigemoto, R., et al. (1999). mGluR7-like receptor and GABA(B) receptor activation enhance neurotoxic effects of N-methyl-D-aspartate in cultured mouse striatal GABAergic neurones. Neuropharmacology 38, 1631-1640. doi: 10.1016/S0028-3908(99)00124-0
136. Lalo, U., Pankratov, Y., Kirchhoff, F., North, R. A., and Verkhratsky, A. (2006). NMDA receptors mediate neuron-to-glia signaling in mouse cortical astrocytes. J. Neurosci. 26, 2673-2683. doi: 10.1523/JNEUROSCI.4689-05.2006
137. Lanctot, K. L., Herrmann, N., Mazzotta, P., Khan, L. R., and Ingber, N. (2004). GABAergic function in Alzheimer’s disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can. J. Psychiatry 49, 439-453.
138. Lanctot, K. L., Herrmann, N., Rothenburg, L., and Eryavec, G. (2007). Behavioral correlates of GABAergic disruption in Alzheimer’s disease. Int. Psychogeriatr. 19, 151-158. doi: 10.1017/S1041610206003899
139. Langmead, C. J., Watson, J., and Reavill, C. (2008). Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol. Ther. 117, 232-243. doi: 10.1016/j.pharmthera.2007.09.009
140. Lasarge, C. L., Banuelos, C., Mayse, J. D., and Bizon, J. L. (2009). Blockade of GABA(B) receptors completely reverses age-related learning impairment. Neuroscience 164, 941-947. doi: 10.1016/j.neuroscience.2009.08.055
141. Le Prince, G., Delaere, P., Fages, C., Lefrancois, T., Touret, M., Salanon, M., et al. (1995). Glutamine synthetase (GS) expression is reduced in senile dementia of the Alzheimer type. Neurochem. Res. 20, 859-862. doi: 10.1007/BF00969698
142. Leao, R. N., Colom, L. V., Borgius, L., Kiehn, O., and Fisahn, A. (2012). Medial septal dysfunction by Abeta-induced KCNQ channel-block in glutamatergic neurons. Neurobiol. Aging 33, 2046-2061. doi: 10.1016/j.neurobiolaging.2011.07.013
143. LeDoux, J. E. (2000). "The amygdala and emotion: a view through fear," in The Amygdala: A Functional Analysis, ed. J. P. Aggleton (New York: Oxford University Press), 289-310.
144. Lee, B. Y., Ban, J. Y., and Seong, Y. H. (2005). Chronic stimulation of GABAA receptor with muscimol reduces amyloid beta protein (25-35)-induced neurotoxicity in cultured rat cortical cells. Neurosci. Res. 52, 347-356. doi: 10.1016/j.neures.2005.04.008
145. Lee, L., Kosuri, P., and Arancio, O. (2014). Picomolar amyloid-beta peptides enhance spontaneous astrocyte calcium transients. J. Alzheimers Dis. 38, 49-62. doi: 10.3233/JAD-130740
146. Lee, M. C., Ting, K. K., Adams, S., Brew, B. J., Chung, R., and Guillemin, G. J. (2010). Characterisation of the expression of NMDA receptors in human astrocytes. PLoS ONE 5:e14123. doi: 10.1371/journal.pone.0014123
147. Leung, L. S., Canning, K. J., and Shen, B. (2005). Hippocampal afterdischarges after GABA(B)-receptor blockade in the freely moving rat. Epilepsia 46, 203-216. doi: 10.1111/j.0013-9580.2005.35804.x
148. Leung, L. S., and Shen, B. (2004). Glutamatergic synaptic transmission participates in generating the hippocampal EEG. Hippocampus 14, 510-525. doi: 10.1002/hipo.10199
149. Levey, A. I., Edmunds, S. M., Koliatsos, V., Wiley, R. G., and Heilman, C. J. (1995). Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J. Neurosci. 15, 4077-4092.
150. Levey, A. I., Kitt, C. A., Simonds, W. F., Price, D. L., and Brann, M. R. (1991). Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci. 11, 3218-3226.
151. Lewohl, J. M., Wilson, W. R., Mayfield, R. D., Brozowski, S. J., Morrisett, R. A., and Harris, R. A. (1999). G-protein-coupled inwardly rectifying potassium channels are targets of alcohol action. Nat. Neurosci. 2, 1084-1090. doi: 10.1038/16012
152. Li, G., Bien-Ly, N., Andrews-Zwilling, Y., Xu, Q., Bernardo, A., Ring, K., et al. (2009). GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell 5, 634-645. doi: 10.1016/j.stem.2009.10.015
153. Li, Y. D., He, H. J., Dong, H. B., Feng, X. Y., Xie, G. M., and Zhang, L. J. (2013). Discriminative analysis of early-stage Alzheimer’s disease and normal aging with automatic segmentation technique in subcortical gray matter structures: a multicenter in vivo MRI volumetric and DTI study. Acta Radiol. 54, 1191-1200. doi: 10.1177/0284185113492971
154. Limon, A., Reyes-Ruiz, J. M., and Miledi, R. (2011). GABAergic drugs and Alzheimer’s disease. Future Med. Chem. 3, 149-153. doi: 10.4155/fmc.10.291
155. Limon, A., Reyes-Ruiz, J. M., and Miledi, R. (2012). Loss of functional GABA(A) receptors in the Alzheimer diseased brain. Proc. Natl. Acad. Sci. U.S.A. 109, 10071-10076. doi: 10.1073/pnas.1204606109
156. Lisman, J. (2005). The theta/gamma discrete phase code occuring during the hippocampal phase precession may be a more general brain coding scheme. Hippocampus 15, 913-922. doi: 10.1002/hipo.20121
157. Liu, X. J., Yuan, L., Yang, D., Han, W. N., Li, Q. S., Yang, W., et al. (2013). Melatonin protects against amyloid-beta-induced impairments of hippocampal LTP and spatial learning in rats. Synapse 67, 626-636. doi: 10.1002/syn.21677
158. Llinas, R., Ribary, U., Contreras, D., and Pedroarena, C. (1998). The neuronal basis for consciousness. Philos. Trans. R. Soc. Lond. B Biol. Sci. 353, 1841-1849. doi: 10.1098/rstb.1998.0336
159. Lopez, O. L. (2011). The growing burden of Alzheimer’s disease. Am. J. Manag. Care 17(Suppl. 13), S339-S345.
160. Loreth, D., Ozmen, L., Revel, F. G., Knoflach, F., Wetzel, P., Frotscher, M., et al. (2012). Selective degeneration of septal and hippocampal GABAergic neurons in a mouse model of amyloidosis and tauopathy. Neurobiol. Dis. 47, 1-12. doi: 10.1016/j.nbd.2012.03.011
161. Lott, I. T., and Head, E. (2005). Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol. Aging 26, 383-389. doi: 10.1016/j.neurobiolaging.2004.08.005
162. Louzada, P. R., Paula Lima, A. C., Mendonca-Silva, D. L., Noel, F., De Mello, F. G., and Ferreira, S. T. (2004). Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer’s disease and other neurological disorders. FASEB J. 18, 511-518. doi: 10.1096/fj.03-0739com
163. Lujan, R., Marron, F. D. V., Aguado, C., and Wickman, K. (2013). New insights into the therapeutic potential of Girk channels. Trends Neurosci. 37, 20-29. doi: 10.1016/j.tins.2013.10.006
164. Lujan, R., Maylie, J., and Adelman, J. P. (2009). New sites of action for GIRK and SK channels. Nat. Rev. Neurosci. 10, 475-480. doi: 10.1038/nrn2668
165. Luscher, C., Jan, L. Y., Stoffel, M., Malenka, R. C., and Nicoll, R. A. (1997). G proteincoupled inwardly rectifying K+ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron 19, 687-695. doi: 10.1016/S0896-6273(00)80381-5
166. Luscher, C., and Slesinger, P. A. (2010). Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease. Nat. Rev. Neurosci. 11, 301-315. doi: 10.1038/nrn2834
167. Lynch, G., Rose, G., and Gall, C. (1977). Anatomical and functional aspects of the septo-hippocampal projections. Ciba Found. Symp. 5-24. doi: 10.1002/9780470720394.ch3
168. Maccioni, R. B., Munoz, J. P., and Barbeito, L. (2001). The molecular bases of Alzheimer’s disease and other neurodegenerative disorders. Arch. Med. Res. 32, 367-381. doi: 10.1016/S0188-4409(01)00316-2
169. Mann, D. M., Yates, P. O., Marcyniuk, B., and Ravindra, C. R. (1986). The topography of plaques and tangles in Down’s syndrome patients of different ages. Neuropathol. Appl. Neurobiol. 12, 447-457. doi: 10.1111/j.1365-2990.1986.tb00053.x
170. Marcade, M., Bourdin, J., Loiseau, N., Peillon, H., Rayer, A., Drouin, D., et al. (2008). Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J. Neurochem. 106, 392-404. doi: 10.1111/j.1471-4159.2008.05396.x
171. Marczynski, T. J. (1995). GABAergic deafferentation hypothesis of brain aging and Alzheimer’s disease; pharmacologic profile of the benzodiazepine antagonist, flumazenil. Rev. Neurosci. 6, 221-258. doi: 10.1515/REVNEURO.1995.6.3.221
172. Marczynski, T. J. (1998). GABAergic deafferentation hypothesis of brain aging and Alzheimer’s disease revisited. Brain Res. Bull. 45, 341-379. doi: 10.1016/S0361-9230(97)00347-X
173. Martins, I. C., Kuperstein, I., Wilkinson, H., Maes, E., Vanbrabant, M., Jonckheere, W., et al. (2008). Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J. 27, 224-233. doi: 10.1038/sj.emboj.7601953
174. Massone, S., Vassallo, I., Fiorino, G., Castelnuovo, M., Barbieri, F., Borghi, R., et al. (2011) 17A, a novel non-coding RNA, regulates GABA B alternative splicing and signaling in response to inflammatory stimuli and in Alzheimer disease. Neurobiol. Dis. 41, 308-317. doi: 10.1016/j.nbd.2010.09.019
175. Matos, M., Augusto, E., Machado, N. J., dos Santos-Rodrigues, A., Cunha, R. A., and Agostinho, P. (2012). Astrocytic adenosine A2A receptors control the amyloid-beta peptide-induced decrease of glutamate uptake. J. Alzheimers Dis. 31, 555-567. doi: 10.3233/JAD-2012-120469
176. Maurice, T., Lockhart, B. P., and Privat, A. (1996). Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res. 706, 181-193. doi: 10.1016/0006-8993(95)01032-7
177. McDonald, A. J. (1985). Immunohistochemical identification of gammaaminobutyric acid-containing neurons in the rat basolateral amygdala. Neurosci. Lett. 53, 203-207. doi: 10.1016/0304-3940(85)90186-7
178. McDonald, A. J., and Augustine, J. R. (1993). Localization of GABA-like immunoreactivity in the monkey amygdala. Neuroscience 52, 281-294. doi: 10.1016/0306-4522(93)90156-A
179. McKeage, K. (2009). Memantine: a review of its use in moderate to severe Alzheimer’s disease. CNS Drugs 23, 881-897. doi: 10.2165/11201020-000000000-00000
180. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34, 939-944. doi: 10.1212/WNL.34.7.939
181. Miledi, R., Duenas, Z., Martinez-Torres, A., Kawas, C. H., and Eusebi, F. (2004). Microtransplantation of functional receptors and channels from the Alzheimer’s brain to frog oocytes. Proc. Natl. Acad. Sci. U.S.A. 101, 1760-1763. doi: 10.1073/pnas.0308224100
182. Mitew, S., Kirkcaldie, M. T., Dickson, T. C., and Vickers, J. C. (2013). Altered synapses and gliotransmission in Alzheimer’s disease and AD model mice. Neurobiol. Aging 34, 2341-2351. doi: 10.1016/j.neurobiolaging.2013.04.010
183. Mizoguchi, H., and Yamada, K. (2011). Pharmacologic treatment with GABA(B) receptor agonist of methamphetamine-induced cognitive impairment in mice. Curr. Neuropharmacol. 9, 109-112. doi: 10.2174/157015911795016976
184. Mizukami, K., Ikonomovic, M. D., Grayson, D. R., Rubin, R. T., Warde, D., Sheffield, R., et al. (1997). Immunohistochemical study of GABA(A) receptor beta2/3 subunits in the hippocampal formation of aged brains with Alzheimer-related neuropathologic changes. Exp. Neurol. 147, 333-345. doi: 10.1006/exnr.1997.6591
185. Mizukami, K., Ikonomovic, M. D., Grayson, D. R., Sheffield, R., and Armstrong, D. M. (1998). Immunohistochemical study of GABAA receptor alpha1 subunit in the hippocampal formation of aged brains with Alzheimer-related neuropathologic changes. Brain Res. 799, 148-155. doi: 10.1016/S0006-8993(98)00437-5
186. Mohamed, A., and Posse de, C. E. (2011). Abeta internalization by neurons and glia. Int. J. Alzheimers Dis. 2011, 127984. doi: 10.4061/2011/127984
187. Moises, H. C., Womble, M. D., Washburn, M. S., and Williams, L. R. (1995). Nerve growth factor facilitates cholinergic neurotransmission between nucleus basalis and the amygdala in rat: an electrophysiological analysis. J. Neurosci. 15, 8131-8142.
188. Moncaster, J. A., Pineda, R., Moir, R. D., Lu, S., Burton, M. A., Ghosh, J. G., et al. (2010). Alzheimer’s disease amyloid-beta links lens and brain pathology in Down syndrome. PLoS ONE 5:e10659. doi: 10.1371/journal.pone.0010659
189. Moore, R. Y. (1993). Principles of synaptic transmission. Ann. N. Y. Acad. Sci. 695, 1-9. doi: 10.1111/j.1749-6632.1993.tb23018.x
190. Moreno, H., Wu, W. E., Lee, T., Brickman, A., Mayeux, R., Brown, T. R., et al. (2007). Imaging the Abeta-related neurotoxicity of Alzheimer disease. Arch. Neurol. 64, 1467-1477. doi: 10.1001/archneur.64.10.1467
191. Mota, S. I., Ferreira, I. L., and Rego, A. C. (2014). Dysfunctional synapse in Alzheimer’s disease-a focus on NMDA receptors. Neuropharmacology 76(Pt A), 16-26. doi: 10.1016/j.neuropharm.2013.08.013
192. Mott, D. D., and Lewis, D. V. (1994). The pharmacology and function of central GABAB receptors. Int. Rev. Neurobiol. 36, 97-223. doi: 10.1016/S0074-7742(08)60304-9
193. Mucke, L., and Selkoe, D. J. (2012). Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2, a006338. doi: 10.1101/cshperspect.a006338
194. Nardone, R., Marth, R., Ausserer, H., Bratti, A., and Tezzon, F. (2006). Reduced short latency afferent inhibition in patients with Down syndrome and Alzheimer-type dementia. Clin. Neurophysiol. 117, 2204-2210. doi: 10.1016/j.clinph.2006.07.134
195. Nava-Mesa, M. O., Jimenez-Diaz, L., Yajeya, J., and Navarro-Lopez, J. D. (2013). Amyloid-beta induces synaptic dysfunction through G protein-gated inwardly rectifying potassium channels in the fimbria-CA3 hippocampal synapse. Front. Cell Neurosci. 7:117. doi: 10.3389/fncel.2013.00117
196. Nilsen, L. H., Witter, M. P., and Sonnewald, U. (2014). Neuronal and astrocytic metabolism in a transgenic rat model of Alzheimer’s disease. J. Cereb. Blood Flow Metab. 34, 906-914. doi: 10.1038/jcbfm.2014.37
197. O’Mahony, S., Harkany, T., Rensink, A. A., Abraham, I., De Jong, G. I., Varga, J. L., et al. (1998). Beta-amyloid-induced cholinergic denervation correlates with enhanced nitric oxide synthase activity in rat cerebral cortex: reversal by NMDA receptor blockade. Brain Res. Bull. 45, 405-411. doi: 10.1016/S0361-9230(97)00405-X
198. Ondrejcak, T., Klyubin, I., Hu, N. W., Barry, A. E., Cullen, W. K., and Rowan, M. J. (2010). Alzheimer’s disease amyloid beta-protein and synaptic function. Neuromolecular Med. 12, 13-26. doi: 10.1007/s12017-009-8091-0
199. Oren, I., Mann, E. O., Paulsen, O., and Hajos, N. (2006). Synaptic currents in anatomically identified CA3 neurons during hippocampal gamma oscillations in vitro. J. Neurosci. 26, 9923-9934. doi: 10.1523/JNEUROSCI.1580-06.2006
200. Palma, E., Torchia, G., Limatola, C., Trettel, F., Arcella, A., Cantore, G., et al. (2005). BDNF modulates GABAA receptors microtransplanted from the human epileptic brain to Xenopus oocytes. Proc. Natl. Acad. Sci. U.S.A. 102, 1667-1672. doi: 10.1073/pnas.0409442102
201. Palop, J. J., Chin, J., Roberson, E. D., Wang, J., Thwin, M. T., Bien-Ly, N., et al. (2007). Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease. Neuron 55, 697-711. doi: 10.1016/j.neuron.2007.07.025
202. Palop, J. J., and Mucke, L. (2009). Epilepsy and cognitive impairments in Alzheimer disease. Arch. Neurol. 66, 435-440. doi: 10.1001/archneurol.2009.15
203. Palop, J. J., and Mucke, L. (2010a). Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat. Neurosci. 13, 812-818. doi: 10.1038/nn.2583
204. Palop, J. J., and Mucke, L. (2010b). Synaptic depression and aberrant excitatory network activity in Alzheimer’s disease: two faces of the same coin? Neuromolecular Med. 12, 48-55. doi: 10.1007/s12017-009-8097-7
205. Palygin, O., Lalo, U., and Pankratov, Y. (2011). Distinct pharmacological and functional properties of NMDA receptors in mouse cortical astrocytes. Br. J. Pharmacol. 163, 1755-1766. doi: 10.1111/j.1476-5381.2011.01374.x
206. Palygin, O., Lalo, U., Verkhratsky, A., and Pankratov, Y. (2010). Ionotropic NMDA and P2X1/5 receptors mediate synaptically induced Ca2+ signalling in cortical astrocytes. Cell Calcium 48, 225-231. doi: 10.1016/j.ceca.2010.09.004
207. Panatier, A., Theodosis, D. T., Mothet, J. P., Touquet, B., Pollegioni, L., Poulain, D. A., et al. (2006). Glia-derived D-serine controls NMDA receptor activity and synaptic memory. Cell 125, 775-784. doi: 10.1016/j.cell.2006.02.051
208. Parameshwaran, K., Dhanasekaran, M., and Suppiramaniam, V. (2008). Amyloid beta peptides and glutamatergic synaptic dysregulation. Exp. Neurol. 210, 7-13. doi: 10.1016/j.expneurol.2007.10.008
209. Parfenova, H., Tcheranova, D., Basuroy, S., Fedinec, A. L., Liu, J., and Leffler, C. W. (2012). Functional role of astrocyte glutamate receptors and carbon monoxide in cerebral vasodilation response to glutamate. Am. J. Physiol. Heart Circ. Physiol. 302, H2257-H2266. doi: 10.1152/ajpheart.01011.2011
210. Pascual, O., Casper, K. B., Kubera, C., Zhang, J., Revilla-Sanchez, R., Sul, J. Y., et al. (2005). Astrocytic purinergic signaling coordinates synaptic networks. Science 310, 113-116. doi: 10.1126/science.1116916
211. Paula-Lima, A. C., Louzada, P. R., De Mello, F. G., and Ferreira, S. T. (2003). Neuroprotection against Abeta and glutamate toxicity by melatonin: are GABA receptors involved? Neurotox. Res. 5, 323-327. doi: 10.1007/BF03033152
212. Perea, G., Navarrete, M., and Araque, A. (2009). Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci. 32, 421-431. doi: 10.1016/j.tins.2009.05.001
213. Prosser, H. M., Gill, C. H., Hirst, W. D., Grau, E., Robbins, M., Calver, A., et al. (2001). Epileptogenesis and enhanced prepulse inhibition in GABA(B1)-deficient mice. Mol. Cell. Neurosci. 17, 1059-1070. doi: 10.1006/mcne.2001.0995
214. Puma, C., and Bizot, J. C. (1999). Hippocampal theta rhythm in anesthetized rats: role of AMPA glutamate receptors. Neuroreport 10, 2297-2300. doi: 10.1097/00001756-199908020-00014
215. Rainnie, D. G., Asprodini, E. K., and Shinnick-Gallagher, P. (1991). Excitatory transmission in the basolateral amygdala. J. Neurophysiol. 66, 986-998.
216. Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., et al. (1999). Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol. Psychiatry 45, 1085-1098. doi: 10.1016/S0006-3223(99)00041-4
217. Ramos, B., Baglietto-Vargas, D., Del Rio, J. C., Moreno-Gonzalez, I., Santa-Maria, C., Jimenez, S., et al. (2006). Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer’s disease. Neurobiol. Aging 27, 1658-1672. doi: 10.1016/j.neurobiolaging.2005.09.022
218. Ramos-Hunter, S. J., Engers, D. W., Kaufmann, K., Du, Y., Lindsley, C. W., Weaver, C. D., et al. (2013). Discovery and SAR of a novel series of GIRK1/2 and GIRK1/4 activators. Bioorg. Med. Chem. Lett. 23, 5195-5198. doi: 10.1016/j.bmcl.2013.07.002
219. Raymond, C. R., Ireland, D. R., and Abraham, W. C. (2003). NMDA receptor regulation by amyloid-beta does not account for its inhibition of LTP in rat hippocampus. Brain Res. 968, 263-272. doi: 10.1016/S0006-8993(03)02269-8
220. Reinikainen, K. J., Paljarvi, L., Huuskonen, M., Soininen, H., Laakso, M., and Riekkinen, P. J. (1988). A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer’s disease. J. Neurol. Sci. 84, 101-116. doi: 10.1016/0022-510X(88)90179-7
221. Resende, R., Pereira, C., Agostinho, P., Vieira, A. P., Malva, J. O., and Oliveira, C. R. (2007). Susceptibility of hippocampal neurons to Abeta peptide toxicity is associated with perturbation of Ca2+ homeostasis. Brain Res. 1143, 11-21. doi: 10.1016/j.brainres.2007.01.071
222. Rissman, R. A., De Blas, A. L., and Armstrong, D. M. (2007). GABA(A) receptors in aging and Alzheimer’s disease. J. Neurochem. 103, 1285-1292. doi: 10.1111/j.1471-4159.2007.04832.x
223. Rissman, R. A., Mishizen-Eberz, A. J., Carter, T. L., Wolfe, B. B., De Blas, A. L., Miralles, C. P., et al. (2003). Biochemical analysis of GABA(A) receptor subunits alpha 1, alpha 5, beta 1, beta 2 in the hippocampus of patients with Alzheimer’s disease neuropathology. Neuroscience 120, 695-704. doi: 10.1016/S0306-4522(03)00030-7
224. Robinson, S. R. (2000). Neuronal expression of glutamine synthetase in Alzheimer’s disease indicates a profound impairment of metabolic interactions with astrocytes. Neurochem. Int. 36, 471-482. doi: 10.1016/S0197-0186(99)00150-3
225. Rockwood, K., Beattie, B. L., Eastwood, M. R., Feldman, H., Mohr, E., Pryse-Phillips, W., et al. (1997). A randomized, controlled trial of linopirdine in the treatment of Alzheimer’s disease. Can. J. Neurol. Sci. 24, 140-145.
226. Rovira, C., Arbez, N., and Mariani, J. (2002). Abeta(25-35) and Abeta(1-40) act on different calcium channels in CA1 hippocampal neurons. Biochem. Biophys. Res. Commun. 296, 1317-1321. doi: 10.1016/S0006-291X(02)02072-7
227. Rubio, S. E., Vega-Flores, G., Martinez, A., Bosch, C., Perez-Mediavilla, A., Del, R. J., et al. (2012). Accelerated aging of the GABAergic septohippocampal pathway and decreased hippocampal rhythms in a mouse model of Alzheimer’s disease. FASEB J. 26, 4458-4467. doi: 10.1096/fj.12-208413
228. Sabbagh, M. N. (2009). Drug development for Alzheimer’s disease: where are we now and where are we headed? Am. J. Geriatr. Pharmacother. 7, 167-185. doi: 10.1016/j.amjopharm.2009.06.003
229. Sago, H., Carlson, E. J., Smith, D. J., Kilbridge, J., Rubin, E. M., Mobley, W. C., et al. (1998). Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc. Natl. Acad. Sci. U.S.A. 95, 6256-6261. doi: 10.1073/pnas.95.11.6256
230. Sanchez, P. E., Zhu, L., Verret, L., Vossel, K. A., Orr, A. G., Cirrito, J. R., et al. (2012). Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proc. Natl. Acad. Sci. U.S.A. 109, E2895-E2903. doi: 10.1073/pnas.1121081109
231. Santos-Torres, J., Fuente, A., Criado, J. M., Riolobos, A. S., Heredia, M., and Yajeya, J. (2007). Glutamatergic synaptic depression by synthetic amyloid beta-peptide in the medial septum. J. Neurosci. Res. 85, 634-648. doi: 10.1002/jnr.21150
232. Sarup, A., Larsson, O. M., and Schousboe, A. (2003). GABA transporters and GABA-transaminase as drug targets. Curr. Drug Targets CNS Neurol. Disord. 2, 269-277. doi: 10.2174/1568007033482788
233. Sawada, M., and Ichinose, M. (1996). Amyloid beta proteins reduce the GABA-induced Cl-current in identified Aplysia neurons. Neurosci. Lett. 213, 213-215. doi: 10.1016/0304-3940(96)12847-0
234. Schipper, H. M., Bennett, D. A., Liberman, A., Bienias, J. L., Schneider, J. A., Kelly, J., et al. (2006). Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol. Aging 27, 252-261. doi: 10.1016/j.neurobiolaging.2005.01.016
235. Schuler, V., Lüscher, C., Blanchet, C., Klix, N., Sansig, G., Klebs, K., et al. (2001). Epilepsy, hyperalgesia, impaired memory, and loss of pre- and postsynaptic GABA(B) responses in mice lacking GABA[B(1)]. Neuron 31, 47-58. doi: 10.1016/S0896-6273(01)00345-2
236. Scott, S. A., DeKosky, S. T., Sparks, D. L., Knox, C. A., and Scheff, S. W. (1992). Amygdala cell loss and atrophy in Alzheimer’s disease. Ann. Neurol. 32, 555-563. doi: 10.1002/ana.410320412
237. Sederberg, P. B., Schulze-Bonhage, A., Madsen, J. R., Bromfield, E. B., McCarthy, D. C., Brandt, A., et al. (2007). Hippocampal and neocortical gamma oscillations predict memory formation in humans. Cereb. Cortex 17, 1190-1196. doi: 10.1093/cercor/bhl030
238. Selkoe, D. J. (2002). Alzheimer’s disease is a synaptic failure. Science 298, 789-791. doi: 10.1126/science.1074069
239. Seppala, T. T., Nerg, O., Koivisto, A. M., Rummukainen, J., Puli, L., Zetterberg, H., et al. (2012). CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 78, 1568-1575. doi: 10.1212/WNL.0b013e3182563bd0
240. Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., et al. (2008). Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842. doi: 10.1038/nm1782
241. Shi, J. Q., Wang, B. R., Tian, Y. Y., Xu, J., Gao, L., Zhao, S. L., et al. (2013). Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice. CNS Neurosci. Ther. 19, 871-881. doi: 10.1111/cns.12144
242. Siarey, R. J., Carlson, E. J., Epstein, C. J., Balbo, A., Rapoport, S. I., and Galdzicki, Z. (1999). Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Neuropharmacology 38, 1917-1920. doi: 10.1016/S0028-3908(99)00083-0
243. Simon, A. P., Poindessous-Jazat, F., Dutar, P., Epelbaum, J., and Bassant, M. H. (2006). Firing properties of anatomically identified neurons in the medial septum of anesthetized and unanesthetized restrained rats. J. Neurosci. 26, 9038-9046. doi: 10.1523/JNEUROSCI.1401-06.2006
244. Singer, W. (1993). Synchronization of cortical activity and its putative role in information processing and learning. Annu. Rev. Physiol. 55, 349-374. doi: 10.1146/annurev.ph.55.030193.002025
245. Smith, B. N., and Dudek, F. E. (1996). Amino acid-mediated regulation of spontaneous synaptic activity patterns in the rat basolateral amygdala. J. Neurophysiol. 76, 1958-1967.
246. Soderman, A., Mikkelsen, J. D., West, M. J., Christensen, D. Z., and Jensen, M. S. (2011). Activation of nicotinic alpha(7) acetylcholine receptor enhances long term potentation in wild type mice but not in APP(swe)/PS1DeltaE9 mice. Neurosci. Lett. 487, 325-329. doi: 10.1016/j.neulet.2010.10.049
247. Soderman, A., Thomsen, M. S., Hansen, H. H., Nielsen, E. O., Jensen, M. S., West, M. J., et al. (2008). The nicotinic alpha7 acetylcholine receptor agonist ssr180711 is unable to activate limbic neurons in mice overexpressing human amyloid-beta1-42. Brain Res. 1227, 240-247. doi: 10.1016/j.brainres.2008.06.062
248. Somogyi, P., and Klausberger, T. (2005). Defined types of cortical interneurone structure space and spike timing in the hippocampus. J. Physiol. 562, 9-26. doi: 10.1113/jphysiol.2004.078915
249. Soto, C. (2003). Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4, 49-60. doi: 10.1038/nrn1007
250. Sotty, F., Danik, M., Manseau, F., Laplante, F., Quirion, R., and Williams, S. (2003). Distinct electrophysiological properties of glutamatergic, cholinergic and GABAergic rat septohippocampal neurons: novel implications for hippocampal rhythmicity. J. Physiol. 551, 927-943. doi: 10.1113/jphysiol.2003.046847
251. Spencer, J. P., Weil, A., Hill, K., Hussain, I., Richardson, J. C., Cusdin, F. S., et al. (2006). Transgenic mice over-expressing human beta-amyloid have functional nicotinic alpha 7 receptors. Neuroscience 137, 795-805. doi: 10.1016/j.neuroscience.2005.10.007
252. Spires-Jones, T., and Knafo, S. (2012). Spines, plasticity, and cognition in Alzheimer’s model mice. Neural Plast. 2012, 319836. doi: 10.1155/2012/319836
253. Stewart, M., and Fox, S. E. (1990). Do septal neurons pace the hippocampal theta rhythm? Trends Neurosci. 13, 163-168. doi: 10.1016/0166-2236(90)90040-H
254. Stonnington, C. M., Snyder, P. J., Hentz, J. G., Reiman, E. M., and Caselli, R. J. (2009). Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers. J. Clin. Psychiatry 70, 1379-1384. doi: 10.4088/JCP.08m04593
255. Sun, B., Halabisky, B., Zhou, Y., Palop, J. J., Yu, G., Mucke, L., et al. (2009). Imbalance between GABAergic and Glutamatergic Transmission Impairs Adult Neurogenesis in an Animal Model of Alzheimer’s Disease. Cell Stem Cell 5, 624-633. doi: 10.1016/j.stem.2009.10.003
256. Sun, M. K., and Alkon, D. L. (2002). Impairment of hippocampal CA1 heterosynaptic transformation and spatial memory by beta-amyloid(25-35). J. Neurophysiol. 87, 2441-2449. doi: 10.1152/jn.00230.2001
257. Sunyer, B., Diao, W. F., Kang, S. U., An, G., Boddul, S., and Lubec, G. (2008). Cognitive enhancement by SGS742 in OF1 mice is linked to specific hip-pocampal protein expression. J. Proteome Res. 7, 5237-5253. doi: 10.1021/pr800594b
258. Swanberg, M. M., Tractenberg, R. E., Mohs, R., Thal, L. J., and Cummings, J. L. (2004). Executive dysfunction in Alzheimer disease. Arch. Neurol. 61, 556-560. doi: 10.1001/archneur.61.4.556
259. Swanson, L. W., and Petrovich, G. D. (1998). What is the amygdala? Trends Neurosci. 21, 323-331. doi: 10.1016/S0166-2236(98)01265-X
260. Takahashi, H., Brasnjevic, I., Rutten, B. P., van der Kolk, N., Perl, D. P., Bouras, C., et al. (2010). Hippocampal interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer’s disease. Brain Struct. Funct. 214, 145-160. doi: 10.1007/s00429-010-0242-4
261. Talantova, M., Sanz-Blasco, S., Zhang, X., Xia, P., Akhtar, M. W., Okamoto, S., et al. (2013). Abeta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc. Natl. Acad. Sci. U.S.A. 110, E2518-E2527. doi: 10.1073/pnas.1306832110
262. Tariot, P. N., Schneider, L. S., Cummings, J., Thomas, R. G., Raman, R., Jakimovich, L. J., et al. (2011). Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch. Gen. Psychiatry 68, 853-861. doi: 10.1001/archgenpsychiatry.2011.72
263. Terry, R. D. (2004). Tangles precede plaques but don’t cause them. Neurobiol. Aging 25, 741-742. doi: 10.1016/j.neurobiolaging.2003.12.013
264. Thathiah, A., and De, S. B. (2009). G protein-coupled receptors, cholinergic dysfunction, and Abeta toxicity in Alzheimer’s disease. Sci. Signal. 2, re8. doi: 10.1126/scisignal.293re8
265. Thathiah, A., and De, S. B. (2011). The role of G protein-coupled receptors in the pathology of Alzheimer’s disease. Nat. Rev. Neurosci. 12, 73-87. doi: 10.1038/nrn2977
266. Tosun, D., Joshi, S., and Weiner, M. W. (2013). Neuroimaging predictors of brain amyloidosis in mild cognitive impairment. Ann. Neurol. doi: 10.1002/ana.23921 [Epub ahead of print].
267. Tsuchiya, K., and Kosaka, K. (1990). Neuropathological study of the amygdala in presenile Alzheimer’s disease. J. Neurol. Sci. 100, 165-173. doi: 10.1016/0022-510X(90)90029-M
268. Tyszkiewicz, J. P., and Yan, Z. (2005). beta-Amyloid peptides impair PKC-dependent functions of metabotropic glutamate receptors in prefrontal cortical neurons. J. Neurophysiol. 93, 3102-3111. doi: 10.1152/jn.00939.2004
269. Ueda, Y., Doi, T., Nagatomo, K., Tokumaru, J., Takaki, M., and Willmore, L. J. (2007). Effect of levetiracetam on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl3 injection. Brain Res. 1151, 55-61. doi: 10.1016/j.brainres.2007.03.021
270. Uemura, K., Kuzuya, A., Aoyagi, N., Ando, K., Shimozono, Y., Ninomiya, H., et al. (2007). Amyloid beta inhibits ectodomain shedding of N-cadherin via down-regulation of cell-surface NMDA receptor. Neuroscience 145, 5-10. doi: 10.1016/j.neuroscience.2006.12.022
271. Um, J. W., Kaufman, A. C., Kostylev, M., Heiss, J. K., Stagi, M., Takahashi, H., et al. (2013). Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron 79, 887-902. doi: 10.1016/j.neuron.2013.06.036
272. Vandevrede, L., Tavassoli, E., Luo, J., Qin, Z., Yue, L., Pepperberg, D. R., et al. (2013). Novel analogues of chlormethiazole are neuroprotective in four cellular models of neurodegeneration by a mechanism with variable dependence on GABA receptor potentiation. Br. J. Pharmacol. 171, 389-402. doi: 10.1111/bph.12454
273. Vereecken, T. H., Vogels, O. J., and Nieuwenhuys, R. (1994). Neuron loss and shrinkage in the amygdala in Alzheimer’s disease. Neurobiol. Aging 15, 45-54. doi: 10.1016/0197-4580(94)90143-0
274. Vergnes, M., Boehrer, A., Simler, S., Bernasconi, R., and Marescaux, C. (1997). Opposite effects of GABAB receptor antagonists on absences and convulsive seizures. Eur. J. Pharmacol. 332, 245-255. doi: 10.1016/S0014-2999(97)01085-6
275. Verkhratsky, A., and Kirchhoff, F. (2007). NMDA Receptors in glia. Neuroscientist 13, 28-37. doi: 10.1177/1073858406294270
276. Verret, L., Mann, E. O., Hang, G. B., Barth, A. M., Cobos, I., Ho, K., et al. (2012). Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149, 708-721. doi: 10.1016/j.cell.2012.02.046
277. Villette, V., Poindessous-Jazat, F., Bellessort, B., Roullot, E., Peterschmitt, Y., Epelbaum, J., et al. (2012). A new neuronal target for β-amyloid peptide in the rat hippocampus. Neurobiol. Aging 33, 1126.e1-1126.e14. doi: 10.1016/j.neurobiolaging.2011.11.024
278. Villette, V., Poindessous-Jazat, F., Simon, A., Lena, C., Roullot, E., Bellessort, B., et al. (2010). Decreased rhythmic GABAergic septal activity and memory-associated theta oscillations after hippocampal amyloid-beta pathology in the rat. J. Neurosci. 30, 10991-11003. doi: 10.1523/JNEUROSCI.6284-09.2010
279. Vincent, A. J., Gasperini, R., Foa, L., and Small, D. H. (2010). Astrocytes in Alzheimer’s disease: emerging roles in calcium dysregulation and synaptic plasticity. J. Alzheimers Dis. 22, 699-714. doi: 10.3233/JAD-2010-101089
280. Vinogradova, O. S., Kitchigina, V. F., and Zenchenko, C. I. (1998). Pacemaker neurons of the forebrain medical septal area and theta rhythm of the hippocampus. Membr. Cell Biol. 11, 715-725.
281. Vossel, K. A., Beagle, A. J., Rabinovici, G. D., Shu, H., Lee, S. E., Naasan, G., et al. (2013). Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 70, 1158-1166. doi: 10.1001/jamaneurol.2013.136
282. Wang, H. Y., Lee, D. H., D’Andrea, M. R., Peterson, P. A., Shank, R. P., and Reitz, A. B. (2000). beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer’s disease pathology. J. Biol. Chem. 275, 5626-5632. doi: 10.1074/jbc.275.8.5626
283. Wang, Y., Zhang, G., Zhou, H., Barakat, A., and Querfurth, H. (2009). Opposite effects of low and high doses of Abeta42 on electrical network and neuronal excitability in the rat prefrontal cortex. PLoS ONE 4:e8366. doi: 10.1371/journal.pone.0008366
284. Washburn, M. S., and Moises, H. C. (1992). Muscarinic responses of rat basolateral amygdaloid neurons recorded in vitro. J. Physiol. 449, 121-154.
285. Webster, M. J., O’Grady, J., Kleinman, J. E., and Weickert, C. S. (2005). Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 133, 453-461. doi: 10.1016/j.neuroscience.2005.02.037
286. Wei, Z. H., He, Q. B., Wang, H., Su, B. H., and Chen, H. Z. (2007). Meta-analysis: the efficacy of nootropic agent cerebrolysin in the treatment of Alzheimer’s disease. J. Neural. Transm. 114, 629-634. doi: 10.1007/s00702-007-0630-y
287. Wen, W., Wu, W., Romaine, I. M., Kaufmann, K., Du, Y., Sulikowski, G. A., et al. (2013). Discovery of ‘molecular switches’ within a GIRK activator scaffold that afford selective GIRK inhibitors. Bioorg. Med. Chem. Lett. 23, 4562-4566. doi: 10.1016/j.bmcl.2013.06.023
288. Whorton, M. R., and MacKinnon, R. (2011). Crystal structure of the mammalian GIRK2 K+ channel and gating regulation by G proteins, PIP2, and sodium. Cell 147, 199-208. doi: 10.1016/j.cell.2011.07.046
289. Wickman, K., Karschin, C., Karschin, A., Picciotto, M. R., and Clapham, D. E. (2000). Brain localization and behavioral impact of the G-protein-gated K+ channel subunit GIRK4. J. Neurosci. 20, 5608-5615.
290. Wolfe, M. S. (2010a). Alzheimer’s disease drug discovery-11th international conference-promising new therapeutic approaches. 27-28 September 2010, Jersey City, NJ, USA. IDrugs 13, 825-827.
291. Wolfe, M. S. (2010b). Alzheimer’s disease drug discovery-11th international conference-targeting pathological tau. 27-28 September 2010, Jersey City, NJ, USA. IDrugs 13, 828-829.
292. Wu, W., and Small, S. A. (2006). Imaging the earliest stages of Alzheimer’s disease. Curr. Alzheimer Res. 3, 529-539. doi: 10.2174/156720506779025161
293. Xiong, H., Baskys, A., and Wojtowicz, J. M. (1996). Brain-derived peptides inhibit synaptic transmission via presynaptic GABAB receptors in CA1 area of rat hippocampal slices. Brain Res. 737, 188-194. doi: 10.1016/0006-8993(96)00731-7
294. Xu, X., An, L., Mi, X., and Zhang, T. (2013). Impairment of cognitive function and synaptic plasticity associated with alteration of information flow in theta and gamma oscillations in melamine-treated rats. PLoS ONE 8:e77796. doi: 10.1371/journal.pone.0077796
295. Yajeya, J., de la Fuente, J. A., Bajo, V. M., Riolobos, A. S., Heredia, M., and Criado, J. M. (1999). Muscarinic activation of a non-selective cationic conductance in pyramidal neurons in rat basolateral amygdala. Neuroscience 88, 159-167. doi: 10.1016/S0306-4522(98)00210-3
296. Yajeya, J., de la Fuente, J. A., Criado, J. M., Bajo, V., Sanchez-Riolobos, A., and Heredia, M. (2000). Muscarinic agonist carbachol depresses excitatory synaptic transmission in the rat basolateral amygdala in vitro. Synapse 38, 151-160. doi: 10.1002/1098-2396(200011)38:2<151::AID-SYN6>3.0.CO;2-K
297. Yajeya, J., de la Fuente, J. A., Merchan, M. A., Riolobos, A. S., Heredia, M., and Criado, J. M. (1997). Cholinergic responses of morphologically and electrophysiologically characterized neurons of the basolateral complex in rat amygdala slices. Neuroscience 78, 731-743. doi: 10.1016/S0306-4522(96)00614-8
298. Yamaguchi, Y., and Kawashima, S. (2001). Effects of amyloid-beta-(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. Eur. J. Pharmacol. 412, 265-272. doi: 10.1016/S0014-2999(01)00730-0
299. Yamakura, T., Lewohl, J. M., and Harris, R. A. (2001). Differential effects of general anesthetics on G protein-coupled inwardly rectifying and other potassium channels. Anesthesiology 95, 144-153. doi: 10.1097/00000542-200107000-00025
300. Yang, K., Belrose, J., Trepanier, C. H., Lei, G., Jackson, M. F., and MacDonald, J. F. (2011). Fyn, a potential target for Alzheimer’s disease. J. Alzheimers Dis. 27, 243-252. doi: 10.3233/JAD-2011-110353
301. Yang, Y., Ge, W., Chen, Y., Zhang, Z., Shen, W., Wu, C., et al. (2003). Contribution of astrocytes to hippocampal long-term potentiation through release of D-serine. Proc. Natl. Acad. Sci. U.S.A. 100, 15194-15199. doi: 10.1073/pnas.2431073100
302. Yew, D. T., Li, W. P., Webb, S. E., Lai, H. W., and Zhang, L. (1999). Neurotransmitters, peptides, and neural cell adhesion molecules in the cortices of normal elderly humans and Alzheimer patients: a comparison. Exp. Gerontol. 34, 117-133. doi: 10.1016/S0531-5565(98)00017-5
303. Yoshiike, Y., Kimura, T., Yamashita, S., Furudate, H., Mizoroki, T., Murayama, M., et al. (2008). GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS ONE 3:e3029. doi: 10.1371/journal.pone.0003029
304. Young, A. B. (1987). Cortical amino acidergic pathways in Alzheimer’s disease. J. Neural Transm. Suppl. 24, 147-152.
305. Yow, T. T., Pera, E., Absalom, N., Heblinski, M., Johnston, G. A., Hanrahan, J. R., et al. (2011). Naringin directly activates inwardly rectifying potassium channels at an overlapping binding site to tertiapin-Q. Br. J. Pharmacol. 163, 1017-1033. doi: 10.1111/j.1476-5381.2011.01315.x
306. Zald, D. H. (2003). The human amygdala and the emotional evaluation of sensory stimuli. Brain Res. Brain Res. Rev. 41, 88-123. doi: 10.1016/S0165-0173(02)00248-5
307. Zemankovics, R., Veres, J. M., Oren, I., and Hajos, N. (2013). Feedforward inhibition underlies the propagation of cholinergically induced gamma oscil-lations from hippocampal CA3 to CA1. J. Neurosci. 33, 12337-12351. doi: 10.1523/JNEUROSCI.3680-12.2013
308. Zhang, C., Cheng, Y., Wang, H., Wang, C., Wilson, S. P., Xu, J., et al. (2014). RNA interference-mediated knockdown of long-form phosphodiesterase-4D (PDE4D) enzyme reverses amyloid-beta42-induced memory deficits in mice. J. Alzheimers Dis. 38, 269-280. doi: 10.3233/JAD-122236
309. Zhang, C. F., and Yang, P. (2006). Zinc-induced aggregation of Abeta (10-21) potentiates its action on voltage-gated potassium channel. Biochem. Biophys. Res. Commun. 345, 43-49. doi: 10.1016/j.bbrc.2006.04.044